Alzheimer's Disease
10
Companies
16
Drug Programs
4
Phase 3
0
Upcoming PDUFAs
Eli Lilly
Alzheimer's Blood Test
Eli Lilly and Company
LY2062430
Johnson & Johnson
galantamine ER
Roche
trontinemab
Eli Lilly and Company
Remternetug (IV)
AbbVie Inc.
ABBV-8E12
Avid Bioservices, Inc.
florbetapir 18F
Passage Bio
VG-3927
Acumen Pharmaceuticals
sabirnetug
Biogen
diranersen
Roche
Masupirdin
Roche
Masupirdine
Biogen
Leqembi
Alamar Biosciences
lecanemab
INmune Bio
XPro
Eli Lilly and Company
donanemab-azbt
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| LLY Eli Lilly | Alzheimer's Blood Test | Approved | — | — | — |
| LLY Eli Lilly and Company | LY2062430 | Phase 3 | — | — | — |
| JNJ Johnson & Johnson | galantamine ER | Phase 3 | — | — | — |
| RHHBY Roche | trontinemab | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | Remternetug (IV) | Phase 3 | — | — | — |
| ABBV AbbVie Inc. | ABBV-8E12 | Phase 2 | — | — | — |
| CDMO Avid Bioservices, Inc. | florbetapir 18F | Phase 2 | — | — | — |
| PASG Passage Bio | VG-3927 | Phase 1 | — | — | — |
| ABOS Acumen Pharmaceuticals | sabirnetug | — | — | — | — |
| BIIB Biogen | diranersen | — | — | — | — |
| RHHBY Roche | Masupirdin | — | — | — | — |
| RHHBY Roche | Masupirdine | — | — | — | — |
| BIIB Biogen | Leqembi | — | — | — | — |
| ALMR Alamar Biosciences | lecanemab | — | — | — | — |
| INMB INmune Bio | XPro | — | — | — | — |
| LLY Eli Lilly and Company | donanemab-azbt | — | — | — | — |
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.